Zaloguj Zarejestruj się zadarmo

Inhibrx organizacji Dług / kapitał własny

Jaka jest wartość Dług / kapitał własny organizacji Inhibrx?

Wartość Dług / kapitał własny organizacji Inhibrx, Inc. to 6.08

Jaka jest definicja Dług / kapitał własny?



Wskaźnik zadłużenia kapitału własnego to wskaźnik finansowy wskazujący względną proporcję kapitału własnego i długu wykorzystywanego do finansowania aktywów spółki.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dług / kapitał własny firm w Health Care sektor na NASDAQ w porównaniu do Inhibrx

Czym się zajmuję organizacja Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy z dług / kapitał własny podobne do Inhibrx